Shire surprises by tapping new CEO

Surprise! You're the next CEO. So said Shire to CFO Angus Russell (photo), who got an unexpected promotion to the company's top slot. The board moved present CEO Matt Emmens to non-executive chair, replacing James Cavanaugh, who retires in June. The changes won't take place until Cavanaugh's exit.

So who is Angus Russell? The 51-year old has been CFO at Shire since 1999, helping to usher the company through several mergers. Before that, he worked in finance, strategy, and marketing at several pharma companies, including AstraZeneca.

- check out Shire's statement
- read the report from MarketWatch

Related Articles:
New guard takes over Big Pharma. Report
Shire on lookout for acquisitions. Report
Shire to Massachusetts: Pass incentive bill now. Report
FDA approves Shire's new ulcerative colitis drug. Report

Suggested Articles

Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.

A phase 1 study of the Inlyta-Keytruda regimen, which bears a first-line nod for kidney cancer, got the ax along with several Bavencio tests.

With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, Incyte's other JAK med Jakafi is also looking for a win in that indication.